SPA
PDSB icon

Sherbrooke Park Advisers’s PDS Biotechnology PDSB Stock Holding History

Sherbrooke Park Advisers’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,026
Closed -$22.9K – 853
2024
Q4 		$22.9K Sell
14,026
-26,156
-65% -$69.2K 0.01% 715
2024
Q3 		$153K Buy
+40,182
New +$134K 0.04% 792

Other funds holding PDSB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Sherbrooke Park Advisers's PDSB Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of PDS Biotechnology (PDSB) in Q1 2025, closing a stake of 14,026 shares — an estimated $22.9K sold.

Sherbrooke Park Advisers first reported a position in PDSB in Q3 2024 and held it in 2 quarters. The position peaked at $153K in Q3 2024. 48 funds tracked by Wall St. Rank hold PDSB as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining PDS Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 14,026 PDS Biotechnology shares in Q1 2025, an estimated $22.9K.
  • Sherbrooke Park Advisers first reported a position in PDS Biotechnology in Q3 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's PDS Biotechnology position peaked at $153K in Q3 2024.
  • 48 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.